JPMorgan Chase trades at $286.56, 6.5% above our $265 fair value estimate, with the market pricing peak-cycle profitability as structural. The 15.7% ROE and 31.3% net margin—10-15 percentage points above money-center norms—are unsustainable as net interest income peaked in 2024 and Q4 2025 earnings deteriorated 9.4% sequentially. Our core variant perception: the 1.4% EPS growth is entirely manufactured through 3.6% share count reduction, masking underlying earnings stagnation that will intensify as buyback capacity faces regulatory and mechanical constraints. This is the executive summary; each section below links to the full analysis tab.
| # | thesis point | evidence |
|---|---|---|
| 1 | peak profitability is cyclical, not structural | net margin 31.3% vs 20-22% money-center norm; revenue growth collapsed from +12.3% (2024) to +2.8% (2025); q4 implied net income $13.03b down 9.4% from q2 peak of $14.99b… |
| 2 | eps growth is manufactured through unsustainable buybacks | 100m share reduction (3.6%) contributed ~$0.70-0.80 to $20.02 eps; without buybacks, eps would have declined ~2% vs +1.4% reported; $28.3b estimated 2025 buyback spend… |
| 3 | valuation premium requires flawless execution that 2025 results contradict | p/b 2.1x represents 60-100% premium to bac (~1.1x), c (~1.0x), wfc (~1.3x); p/e 14.2x in-line with peers (bac ~12x, c ~16x, wfc ~14x); roe spread narrowing as jpm net income -2.4% yoy vs peer stabilization… |
| 4 | overdue scb disclosure creates asymmetric regulatory risk | scb deadline august 31, 2025 now 6+ months overdue; resolution expected june-july 2026; 50bps+ increase cuts buybacks to $12-15b from $20-25b, driving 15% downside to ~$240… |
| 5 | credit cost normalization is underappreciated 2026-2027 earnings risk | current provisions ~$5-6b vs normalized $7-8b; 75bps net charge-offs (vs ~35bps currently) reduces eps by $2-3; 11.21x total liabilities/equity amplifies sensitivity to 2% npl increase = $7b equity impairment… |
| trigger | threshold | current | status |
|---|---|---|---|
| revenue growth reacceleration | >8% yoy | 2.8% (2025) | NOT TRIGGERED |
| roe compression | <13% | 15.7% | NOT TRIGGERED |
| cet1 requirement increase | >50bps | UNKNOWN | |
| net interest margin collapse | <2.0% | UNKNOWN |
| date | event | impact | if positive | if negative |
|---|---|---|---|---|
| jun-jul 2026 | scb (stress capital buffer) disclosure | HIGH | scb flat/below 3.0% enables $20b+ 2026 buybacks; p/b sustains 2.0x+; path to $310 bull case (+9%) | 50bps+ increase forces capital retention, buybacks cut to $12-15b; p/b compresses to 1.7-1.8x; ~$240 (-15%) |
| apr 14, 2026 | q1 2026 earnings | HIGH | nii stabilization, deposit beta clarity, cib recovery; confirms soft landing base case… | sequential eps decline below $4.50, nim compression accelerates; margin compression thesis confirmed… |
| jul 2026 | 2026 ccar/stress test results | MEDIUM | g-sib surcharge unchanged, qualitative pass; regulatory overhang removed… | g-sib surcharge increase, leverage ratio hike; capital return constrained for 2-3 years… |
| ongoing | cre credit quality disclosure | MEDIUM | npls stable, reserve coverage adequate; provision normalization delayed to 2027+… | office/multifamily delinquencies spike; 75bps ncos realized; eps cut $2-3, multiple compression to 11-12x… |
| 2026 | succession planning update | MEDIUM | named successor, orderly transition timeline; 'dimon premium' phases out gradually… | abrupt departure, no credible successor; 5-10% valuation premium ($40-75b) evaporates rapidly… |
| period | revenue | net income | eps |
|---|---|---|---|
| fy2023 | $158.1b | $49.6b | $16.23 |
| fy2024 | $177.6b | $58.5b | $19.75 |
| fy2025 | $182.4b | $57.0b | $20.02 |
| method | fair value | vs current |
|---|---|---|
| dcf (5-year) | $265 | -7.5% |
| bull scenario | $310 | +8.2% |
| bear scenario | $200 | -30.2% |
| monte carlo median (10,000 sims) | $250 | -12.8% |
| year | revenue | net income | eps (diluted) | net margin | roe |
|---|---|---|---|---|---|
| 2025 | $182.45b | $57.05b | $20.02 | 31.3% | 15.7% |
JPM offers the rare combination of a fortress balance sheet, best-in-class management execution, and multiple self-help levers—NII stabilization, expense discipline, and capital return acceleration—at 11x forward earnings and 1.6x tangible book, a discount to its 5-year average despite superior positioning. With $3.9 trillion in deposits and unmatched scale economics, JPM will compound book value at 10%+ while returning 80%+ of earnings to shareholders, making it a core financials holding for patient capital.